DayTwo

DayTwo is a pioneering company that focuses on personalized nutrition for metabolic disease. With a slogan of "Precision Nutrition for Metabolic Disease," DayTwo's core mission is to enable individuals to take charge of their health by understanding and optimizing their unique gut microbiome. The company specializes in precision health through microbiome-based insights, which drive personalized dietary recommendations. This includes microbiome analysis for personalized nutrition optimization and predictive dietary recommendations based on individual microbiome composition. The company distinguishes itself through several key points, including advanced technology, which encompasses state-of-the-art sequencing methods and proprietary algorithms. The scientific foundation of DayTwo's work is reinforced by 25 years of diverse patient data and research that has been published in prestigious journals such as Nature, Cell, JAMA, and Diabetes Care. Additionally, DayTwo boasts the world's largest high-resolution sequenced data set, comprising over 90,000 samples, which allows for a truly personalized approach to providing recommendations based on individual microbiome profiles. Founded in 2015 and headquartered in the United States, DayTwo secured a significant Series B investment of £26.30M on 31 May 2021, with a consortium of investors including Cathay Innovation, 10D, aMoon, Lamaison Partners, Micron Ventures, Paolim Capital Markets, Volta Circle, Yair Schindel, Jacky Abitbol. The company's offerings and recent investment position it as a compelling player in the Health Care and Nutrition industries. In essence, DayTwo's innovative approach to personalized nutrition, backed by advanced technology and robust scientific research, has attracted significant investment and positions the company as a leader in the field, with tremendous potential for further growth and impact.